The IPO class of 2026 is likely to receive its first incumbent, after Aktis Oncology set its sights on a public listing that could see proceeds of around $210m. The cancer treatment-focused biotech ...

Something big is lining up for 2026, and it’s not just another IPO cycle. Wall Street is staring at one of the most crowded public-market queues in years, with 190+ companies racing toward the exit at ...

Taking a technology company public is a milestone that brings both opportunity and complexity. While the spotlight often shines on the IPO day, it’s the careful orchestration behind the ...

As the global business community converges at Davos, we are seeing powerful catalysts driving M&A and capital markets activity. The foundational drivers that accelerated business activity in the ...